enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

What happened: enGene Therapeutics (ENGN) held a webinar on preclinical data and clinical case studies for its lead investigational candidate, detalimogene voraplasmid plus surfactant bladder rinse. Why it matters: The call covered the potential benefits and product profile of detalimogene, the impact of adding a surfactant bladder rinse before treatment, and timing of clinical data and regulatory submission. Note: The content contains no concrete figures such as revenue, percentages, prices, or volumes, so the Key numbers line is omitted.

enGene discusses preclinical data and clinical case studies on surfactant bladder rinse treatment.

enGene discusses preclinical data and clinical case studies on surfactant bladder rinse treatment. — impact context not separately stored; see What changed.